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actors including advanced age, prolonged duration of the lesion,
ack of fever and absence of air bronchograms should raise the sus-
icion of TB. Previous exposure to a FQ for >10 days in patients
ith TB is associated with the emergence of FQ-resistant M. tuber-
ulosis isolates. However, rates of M. tuberculosis isolates with
Q resistance are signiﬁcantly higher amongst multidrug-resistant
. tuberculosis isolates than amongst susceptible isolates. Conse-
uently, in countries with TB endemicity, a short-course (5-day)
egimen of a respiratory FQ is still recommended as empirical ther-
py for CAP patients if the patient is at low risk for TB.
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Fluoroquinolones are used widely for the treatment of LRTIs.
he ATS/IDSA guidelines for CAP recommended them as use-
ul choices in many clinical scenarios especially for hospitalized
atients. Concerns have been raised that using ﬂuoroquinolones
or the management of LRTIs will destroy the value of this class
or use particularly in MDR-TB. Arguments center on the notion
hat ﬂuoroquinoloneswillmask the clinical features of TB, delaying
iagnosis and enhancing widespread dissemination. They further
ostulate that the yield of culture-negative TB will increase and
hat, with increasing use of ﬂuoroquinolones, ﬂuoroquinolone-
esistant TB will become increasingly prevalent. Many patients
nfected with TB present with LRTI symptoms and a lung inﬁltrate.
brief treatment course with a ﬂuoroquinolone rarely produces a
apid clinical recovery. Most patients with TB, even when treated
ppropriately, have a very slow radiographic response and often
eteriorate initially. In contrast, bacterial pneumonia usually has
rapid radiographic response especially in previously healthy
oung adults. Studies trying to document delayed diagnosis when
uoroquinolones have been used, have been unable to mount a
ersuasive case. There is no evidence that patients initially treated
ith a ﬂuoroquinolone are more likely to have culture-negative
B. Multiple studies to date have documented a very low rate
f ﬂuoroquinolone-resistant TB throughout the world. There has
een no relationship between prior ﬂuoroquinolone exposure and
he emergence of resistance. The most persuasive relationship
s between ﬂuoroquinolone resistance and multi-drug resistance.
ndiandata suggest amorewidespreadproblemexists but thatmay
ave more to do with ease of availability of all antibiotics without
hysician supervision in that country. If a patient presents with
clinical illness suggestive of TB, ﬂuoroquinolones should not be
sed asmonotherapy. But even if used inpatients ultimately shown
o have TB, a short exposure to a potent ﬂuoroquinolone is unlikely
o delay diagnosis or lead to the emergence of bacterial resistance.
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Fluoroquinolones in TB: The future
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Moxiﬂoxacin has been demonstrated to have excellent activity
against Mycobacterium tuberculosis in vitro and in mouse models.
This encouraging activity against this important human pathogen
is combinedwith a pharmacokinetic proﬁle that permits once a day
dosing. The results of several mouse model studies have suggested
that substitution ofmoxiﬂoxacin for ethambutol or isoniazidmight
allow treatment duration to be shortened to four months. This has
been supported by clinical phase II studies.
A phase III pivotal trial (REMoxTB), is now underway to test reg-
imens built on moxiﬂoxacin and the results of these studies are
eagerly awaited. The test regimens substitute either ethambutol
or isoniazid with moxiﬂoxacin and offer the best chance of reduc-
ing current treatment duration from six months to four, the ﬁrst
improvement in TB treatment for more than ﬁfty years. The trial is
being performed at multiple sites in Africa and Asia.
Fluoroquinolonesalsohavean important role toplay in theman-
agementofpatientswithdrug toxicity aswell asbeingan important
part of the treatment ofmultiple drug resistance forwhich they are
recommended by a number of national and international bodies.
Nevertheless, well controlled clinical trials of the role of ﬂuoro-
quinolones are still required in the management of multiple drug
resistance are required. Further studies investigating regimens that
combine moxiﬂoxacin with repurposed and new agents are now
entering the clinical trial phase.
Resistance to ﬂuoroquinolones is a growing concern due to
the increasing frequency with which resistant strains are being
reported. This emphasises the importance of improving diagnosis
of respiratory tract infection, good antibiotic stewardship and the
use of the modern ﬂuoroquinolones that are least likely to select
for resistance.
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State of the science: Antiretroviral treatment for prevention
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“No virus, no transmission.” In the absence of treatment,
the viral load (the quantity of virus present in blood and sex-
ual secretions) is the strongest predictor of HIV transmission
with unprotected sex, or from infected mother to child. Effective
